17. Kitadai Y, Haruma K, Sumii K, et al (1998) Expression of IL-8 correlates with vascularity in human gastric carcinomas. Am J Pathol 152:93–100

18. Takahashi Y, Bucana CD, Akagi Y, et al (1998) Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. Clin Cancer Res 4:429–434

19. Kitadai Y, Takahashi Y, Haruma K, et al (1999) Transfection of interleukin-8 increases angiogenesis and tumorigenesis of human gastric carcinoma cells in nude mice. Br J Cancer 81:647–653

20. Kitadai Y, Haruma K, Mukaida N, et al (2000) Regulation of disease-progression genes in human gastric carcinoma cells by interleukin-8. Clin. Cancer Res 6:2735–2740

21. Kitadai Y, Sasaki A, Ito M, et al (2003) *Helicobacter pylori* infection influences expression of genes related to angiogenesis and invasion in human gastric carcinoma cells. Biochem Biophys Res Commun 311:809–814

22. Tatematsu M, Tsukamoto T, Inada K (2003) Stem cells and gastric cancer: role of gastric and intestinal mixed intestinal metaplasia. Cancer Sci 94:135–141

23. Ohmura K, Tamura G, Endoh Y, et al (2000) Microsatellite alterations in differentiated-type adenocarcinomas and precancerous lesions of the stomach with special reference to cellular phenotype. Hum Pathol 31:1031–1035

24. Yokozaki H, Shitara Y, Fujimoto J, et al (1999) Alterations of p73 preferentially occur in gastric adenocarcinomas with foveolar epithelial phenotype. Int J Cancer 83:192–196

25. Almeida R, Silva E, Santos-Silva F, et al (2003) Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J Pathol 199:36–40

26. Yamamoto H, Bai YQ, Yuasa Y (2003) Homeodomain protein CDX2 regulates goblet-specific MUC2 gene expression. Biochem Biophys Res Commun 300:813–818

27. Grotzinger C, Kneifel J, Patschan D, et al (2001) LI-cadherin: a marker of gastric metaplasia and neoplasia. Gut 49:73–81

28. Hippo Y, Taniguchi H, Tsutsumi S, et al (2002) Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 62:233–240

29. Yasui W, Oue N, Ito R, et al (2004) Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci 95:385–392

30. Hinoi T, Lucas PC, Kuick R, et al (2002) CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. Gastroenterology 123:1565–1577

31. Oshimo Y, Oue N, Mitani Y, et al (2004) Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma. Pathobiology 71:137–143

32. Oue N, Shigeishi H, Kuniyasu H, et al (2001) Promoter methylation of MGMT is associated with protein loss in gastric carcinomas. Int J Cancer 93:805–809

33. Oue N, Matsumura S, Nakayama H, et al (2003) Expression of theTSP-1 gene and its association with promoter hypermethylation in gastric carcinomas. Oncology 64:423–429

34. Hamai Y, Oue N, Mitani Y, et al (2003) DNA methylation and histone acetylation status of HLTF gene are associated with reduced expression in gastric carcinoma. Cancer Sci 94:692–698

35. Oshimo Y, Oue N, Mitani Y, et al (2004) Frequent epigenetic inactivation of RIZ1 by promoter hypermethylation in human gastric carcinoma. Int J Cancer 110:212–218

36. Satoh A, Toyota M, Itoh F, et al (2003) Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 63:8606–8613

37. Toyota M, Ahuja N, Suzuki H, et al (1999) Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 59:5438–5442

38. Kaneda A, Kaminishi M, Yanagihara K, et al (2002) Identification of silencing of nine genes in human gastric cancers. Cancer Res 62:6645–6650

39. Oue N, Motoshita J, Yokozaki H, et al (2002) Distinct promoter hypermethylation of p16ink4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinoma. J Pathol 198:55–59

40. Oue N, Oshimo Y, Mitani Y, et al (2003) DNA methylation of multiple genes in gastric carcinoma: association with histological type and CpG island methylator phenotype. Cancer Sci 94:901–905

41. Kang GH, Shim Y-H, Jung H-Y, et al (2001) CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 61:2847–2851

42. Rhee I, Bachman KE, Park BH, et al (2002) DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (Lond) 416:552–556

43. Robert M-F, Morin S, Beaulieu N, et al (2003) DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 33:61–65

44. Kouzarides T (1999) Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 9:40–48

45. Kouzarides T (2002) Histone methylation in transcriptional control. Curr Opin Genet Dev 12:198–209

46. Gonzalez CA, Sala N, Capella G (2002) Genetic susceptibility and gastric cancer risk. Int J Cancer 100:249–260

47. Wu M-S, Huang S-P, Chang Y-T, et al (2002) Association of the −160 C → A promoter polymorphism of the *E-cadherin* gene with gastric carcinoma risk. Cancer (Phila) 94:1443–1448

48. Pharoah PDP, Oliveira C, Machado JC, et al (2002) *CDH1* c-160a promoter polymorphism is not associated with risk of stomach cancer. Int J Cancer 101:196–197

49. Watters JW, McLeod HL (2003) Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta 1603:99–111

50. El-Rifai W, Frierson HF Jr, Harper JC, et al (2001) Expression profiling of gastric adenocarcinoma using cDNA array. Int J Cancer 92:832–838

51. Hasegawa S, Furukawa Y, Li M, et al (2002) Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23 040 genes. Cancer Res 62:7012–7017

52. Inoue H, Matsuyama A, Mimori K, et al (2002) Prognostic score of gastric cancer determined by cDNA microarray. Clin Cancer Res 8:3475–3479

53. Zembutsu H, Ohnishi Y, Tsunoda T, et al (2002) Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 62:518–527

54. Velculescu VE, Zhang L, Vogelstein B, et al (1995) Serial analysis of gene expression. Science 270:484–487

55. El-Rafai W, Moskaluk CA, Abdrabbo MK, et al (2002) Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 62:6823–6826

56. Oien KA, Vass JK, Downie I, et al (2003) Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomach. Oncogene 22:4287–4300

57. Lee J-Y, Eom E-M, Kim D-S, et al (2003) Analysis of gene expression profiles of gastric normal and cancer tissues by SAGE. Genomics 82:78–85

58. Oue N, Hamai Y, Mitani Y, et al (2004) Gene expression profile of gastric carcinoma; identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res 64:2397–2405

59. Hicks GG, Singh N, Nashabi A, et al (2000) Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death. Nat Genet 24:175–179

60. Hartupee JC, Zhang H, Bonaldo MF, et al (2001) Isolation and characterization of a cDNA encoding a novel member of the human generating protein family. Biochim Biophys Acta 1518:287–293

61. Zhang X, Huang Q, Yang Z, et al (2004) GW112, a novel antiapoptotic protein that promotes tumor growth. Cancer Res 64:2474–2481

62. Krupnik VE, Sharp JD, Jiang C, et al (1999) Functional and structural diversity of the human Dickkopf gene family. Gene (Amst) 238:301–313

*Color Plates* to appear on the following pages.

FIG. 1. Multiple genetic and epigenetic alterations during stomach carcinogenesis. Words printed in *dark blue* represent genetic alterations and those in *green* represent epigenetic alterations

FIG. 2. Schematic illustration of cancer cells and macrophages in angiogenesis. *MCP-1*, monocyte chemoattractant protein-1; *IL*, interleukin; *TNF-α*, tumor necrosis factor-alpha; *VEGF*, vascular endothelial growth factor; *EGFR*, epidermal growth factor receptor; *PD-ECGF*, platelet-derived endothelial cell growth factor; *IL-8R*, IL-8 receptor


FIG. 3. Strategy to search for novel genes of gastric cancer through gene expression profiles and its clinical implication. *SAGE*, serial analysis of gene expression; *SNP*, single nucleotide polymorphism

Original Paper

Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma

Naohide Oue,[1] Yoshitsugu Mitani,[1] Phyu Phyu Aung,[1] Chouhei Sakakura,[2] Yukio Takeshima,[3] Mayumi Kaneko,[3] Tsuyoshi Noguchi,[4] Hirofumi Nakayama[1] and Wataru Yasui[1]*

[1]Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan
[2]Graduate School of Medical Science, Surgery and Regenerative Medicine, Surgery and Physiology of Digestive System, Kyoto Prefectural University of Medicine, Kyoto, Japan
[3]Department of Pathology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan
[4]Department of Oncological Science (Surgery II), Oita University Faculty of Medicine, Oita, Japan

*Correspondence to:
Wataru Yasui, Department of
Molecular Pathology, Hiroshima
University Graduate School of
Biomedical Sciences, 1-2-3
Kasumi, Minami-ku, Hiroshima,
734-8551, Japan.
E-mail: wyasui@hiroshima-u.ac.jp

Abstract

Regenerating islet-derived family, member 4 (Reg IV) is a candidate marker for cancer and inflammatory bowel disease. In the present study, immunohistochemical analysis of Reg IV was performed in various human neoplastic ($n = 289$) and non-neoplastic tissues. In the stomach, foveolar epithelium was negative for Reg IV, whereas goblet cells of intestinal metaplasia and neuroendocrine cells at the base of intestinal metaplasia expressed Reg IV. Neuroendocrine cells of the small intestine and colon showed strong expression of Reg IV, whereas goblet cells of the small intestine and colon showed weak or no expression of Reg IV. Insulin-producing beta cells of the endocrine pancreas were positive for Reg IV. Among 143 gastric adenocarcinomas, Reg IV expression was detected in 42 (29.4%) and was associated with both the intestinal mucin phenotype and neuroendocrine differentiation. No association was found between Reg IV expression and clinical characteristics such as tumour stage and patient prognosis. Of 36 colorectal adenocarcinomas, 13 (36.1%) were positive for Reg IV, which was associated with tumour stage ($p = 0.0379$, Fisher's exact test). Expression of Reg IV was detected in 14 (93.3%) of 15 colorectal carcinoid tumours. Reg IV expression was also detected in 5 (21.7%) of 23 ductal adenocarcinomas of the pancreas. In contrast, lung cancers ($n = 30$) and breast cancers ($n = 30$) did not express Reg IV. This is the first immunohistochemical analysis of the expression and distribution of Reg IV protein in human tumours. These data suggest that Reg IV is expressed by gastrointestinal and pancreatic tumours, including adenocarcinomas and carcinoid tumours, and that Reg IV is associated with intestinal and neuroendocrine differentiation of the stomach and gastric carcinoma. Copyright © 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Introduction

Gastric carcinoma is one of the most common human cancers. Genes encoding transmembrane/secretory proteins expressed specifically in cancers may be ideal diagnostic biomarkers [1,2].

We previously performed serial analysis of gene expression (SAGE) of four primary gastric carcinomas and identified several genes and tags that may be involved in invasion, metastasis, and carcinogenesis [3]. Of these genes, regenerating islet-derived family, member 4 (*REGIV*) is a candidate gene for cancer-specific expression, at least in gastric carcinoma. Quantitative reverse transcription (RT)-polymerase

chain reaction (PCR) analysis showed that approximately half of the gastric carcinomas analysed overexpressed the *REGIV* gene [3]. Although various normal tissues, including the stomach, intestine, and pancreas, express *REGIV* [4], levels of *REGIV* expression are much lower in normal tissues than in tumour tissues [3]. Overexpression of *REGIV* mRNA was detected in colorectal carcinoma and adenoma by RT-PCR and *in situ* hybridization, respectively [5,6]. It has been reported that high *REGIV* expression is associated with 5-fluorouracil (5-FU) resistance in colon cancer cell lines [5]. In non-neoplastic tissues, immunofluorescence staining revealed that Reg IV (referred to as RELP) co-localizes with chromogranin A in the

neuroendocrine cells of the duodenal epithelium [5,7]. In colonic mucosa, only weak expression of Reg IV protein is observed in selected cells, whereas Reg IV is expressed at higher levels in the cryptal epithelium of the mucosa from patients with ulcerative colitis [7]. Expression of Reg IV protein is detected in the goblet cells of intestinal metaplasia of the stomach [7].

However, the expression and distribution of Reg IV in human tumours remain unclear. Thus, we examined the expression and distribution of Reg IV immunohistochemically in various neoplastic and non-neoplastic human tissues. In addition, because Reg IV is expressed in intestinal metaplasia of the stomach, we investigated the association between Reg IV expression and mucin phenotype in gastric carcinoma. We also examined the co-localization of Reg IV and chromogranin A.

Materials and methods

Tissue samples

Nine gastric carcinomas, nine colorectal carcinomas, nine lung cancers, and nine breast cancers were used for quantitative RT-PCR. The samples were obtained at the time of surgery at Hiroshima University Hospital and affiliated hospitals. We confirmed microscopically that the tumour specimens consisted mainly (>50%) of carcinoma tissue. Samples were frozen immediately in liquid nitrogen and stored at $-80\,^{\circ}$C until use. Non-tumour samples of the heart, lung, stomach, small intestine, colon, liver, pancreas, kidney, bone marrow, peripheral leukocytes, spleen, skeletal muscle, brain, and spinal cord were purchased directly from Clontech (Palo Alto, CA, USA).

For immunohistochemical analysis, we used archival formalin-fixed, paraffin-embedded tissues from 289 patients who had undergone surgical excision or removal of the tumour by polypectomy for gastric carcinoma ($n = 143$), colorectal carcinoma ($n = 36$), pancreatic carcinoma ($n = 23$), lung cancer ($n = 30$), breast cancer ($n = 30$), colorectal carcinoid tumour ($n = 15$), colorectal adenoma ($n = 10$), small cell carcinoma of the uterine cervix ($n = 1$), or small cell carcinoma of the extrahepatic bile ducts ($n = 1$) [8]. The 143 gastric adenocarcinomas were histologically classified as well ($n = 85$) or poorly ($n = 58$) differentiated. Thirty-six colorectal adenocarcinomas were histologically classified as well ($n = 15$), moderately ($n = 15$) or poorly ($n = 3$) differentiated, or mucinous ($n = 3$). All 23 pancreatic carcinomas were ductal adenocarcinomas. Of the 30 lung cancers, ten were squamous cell carcinomas, ten were adenocarcinomas, and ten were large cell neuroendocrine carcinomas. All 30 breast cancers were invasive ductal carcinomas. Tumour staging was carried out according to the TNM staging system [9].

Because written informed consent was not obtained, identifying information for all samples was removed

before analysis for strict privacy protection; the procedure was in accordance with the Ethical Guidelines for Human Genome/Gene Research enacted by the Japanese Government.

Antibodies

Rabbit polyclonal antibodies were raised against His-tagged recombinant Reg IV produced in bacteria and purified with nickel resin (Qiagen, Valencia, CA, USA). Specificity of the anti-Reg IV antibodies was evaluated by ELISA (data not shown). Immunoreactive sera were affinity-purified with the His-tagged recombinant Reg IV protein. We used four antibodies for phenotypic expression analysis of gastric carcinoma: anti-MUC5AC (Novocastra, Newcastle, UK) as a marker of gastric foveolar epithelial cells; anti-MUC6 (Novocastra) as a marker of pyloric gland cells; anti-MUC2 (Novocastra) as a marker of goblet cells in the small intestine and colorectum; and anti-CD10 (Novocastra) as a marker of the microvilli of absorptive cells in the small intestine and colorectum. Anti-chromogranin A antibody (Novocastra) was used as a neuroendocrine marker. Anti-insulin antibody (Nichirei Biosciences, Tokyo, Japan) and anti-glucagon antibody (Euro-Diagnostica, Sweden) were used for analysis of the endocrine pancreas. Antibody against caudal-related homeobox gene 2 (Cdx2) protein was purchased from BioGenex (San Ramon, CA, USA).

Cell lines, expression vector, and transfection

Seven cell lines derived from human gastric carcinoma were used. The TMK-1 cell line was established in our laboratory [10]. Five gastric carcinoma cell lines of the MKN series were kindly provided by Dr T Suzuki. HSC-39 cell line was kindly provided by Dr K Yanagihara [11]. All cell lines were maintained in RPMI 1640 (Nissui Pharmaceutical Co, Ltd, Tokyo, Japan) containing 10% fetal bovine serum (Whittaker, Walkersville, MD, USA) in a humidified atmosphere of 5% CO_2 and 95% air at 37 °C. For constitutive expression of *Reg IV*, cDNA was amplified by PCR and sub-cloned into pcDNA 3.1 (Invitrogen, Carlsbad, CA, USA). Transient transfection was carried out with the FuGENE6 Transfection Reagent (Roche Diagnostics, Indianapolis, IN, USA).

Conventional and quantitative RT-PCR analyses

Total RNA was extracted with an RNeasy Mini Kit (Qiagen), and 1 μg of total RNA was converted to cDNA with a First Strand cDNA Synthesis Kit (Amersham Pharmacia, Little Chalfont, UK). Conventional RT-PCR was performed to investigate *REGIV* mRNA expression in gastric carcinoma cell lines. The amplification products were then separated by 1% agarose gel electrophoresis, stained with ethidium bromide, and visualized under UV light. *ACTB*-specific PCR

products served as internal controls. *REGIV* primer sequences were 5'-CCA AAC AGA TTT GCA GAT CAA GGA-3' (sense) and 5'-TGC AGG AGT TAG CAG AAT CTT GAT-3' (antisense). To analyse the expression of *REGIV* in human tissue samples, we performed real-time RT-PCR. Primer sequences and annealing temperatures were as described previously [3]. PCR was performed with an SYBR Green PCR Core Reagents kit (Applied Biosystems, Foster City, CA, USA). Real-time detection of the emission intensity of SYBR Green bound to double-stranded DNA was performed with an ABI PRISM 7700 Sequence Detection System (Applied Biosystems) as described previously [12]. *ACTB*-specific PCR products were amplified from the same RNA samples and served as internal controls.

Western blot analysis

For western blot analysis, cells and culture medium were lysed as described previously [13]. The culture media were concentrated with the PROTEIN Concentrate Kit (Takara Bio, Inc, Shiga, Japan). The lysates (40 µg) were solubilized in Laemmli sample buffer by boiling and then subjected to 12% SDS-polyacrylamide gel electrophoresis followed by electrotransfer onto a nitrocellulose filter. Peroxidase-conjugated anti-mouse IgG was used in the secondary reaction. The immune complex was visualized with an ECL Western Blot Detection System (Amersham Pharmacia Biotech).

Immunohistochemistry

A modified immunoglobulin enzyme bridge technique (ABC method) was used as described previously [14]. Microwave pretreatment in citrate buffer was performed for 15 min to retrieve antigenicity. Sections were treated consecutively at room temperature with primary antibody for 120 min, biotinylated anti-mouse or anti-rabbit IgG horse serum (diluted 1 : 200) for 30 min, and avidin DH-biotinylated horseradish peroxidase complex (Vectastain ABC Kit; Vector, Burlingame, CA, USA) for 30 min. Peroxidase staining was performed for 10–15 min with a solution of 3,3'-diaminobenzidine tetrahydrochloride in 50 mM Tris–HCl (pH 7.5) containing 0.001% hydrogen peroxide. The sections were counterstained with 0.1% haematoxylin. A result was considered positive if at least 10% of the cells were stained. When fewer than 10% of cancer cells were stained, the immunostaining was considered negative. Specificity of Reg IV staining was confirmed by pre-absorption of the anti-Reg IV antibody with an excess of the appropriate Reg IV protein. Reg IV staining was classified as mucin-like (vesicular) and perinuclear on the basis of alcian blue/periodic acid-Schiff (AB/PAS) staining. When the cells were positive for AB/PAS, we considered the cells to have mucin-like staining of Reg IV. If the cells were not positive for AB/PAS, we considered the cells to have perinuclear staining of Reg IV.

Phenotypic analysis of gastric carcinoma

Gastric carcinomas were classified into four phenotypes: gastric (G) type; intestinal (I) type; gastric and intestinal mixed (GI) type; and unclassified (N) type. The criteria [15] for the classification of G type and I type were as follows. Gastric cancers in which more than 10% of the section consisted of at least one gastric or intestinal epithelial cell phenotype were classified as G-type or I-type cancers, respectively. Those sections that showed both gastric and intestinal phenotypes were classified as GI type, and those that lacked both the gastric and the intestinal phenotypes were classified as N type.

Double immunofluorescence staining

Dewaxed tissue sections were immersed in methanol containing 0.03% hydrogen peroxide for 30 min to block endogenous peroxidase activity. Microwave pretreatment in citrate buffer was performed for 15 min to retrieve antigenicity. Sections were then incubated with normal horse serum for 30 min to block non-specific antibody binding sites. Sections were treated consecutively at room temperature with primary antibody for 120 min, and immunocomplexes were detected with Alexa Fluor 546-conjugated goat anti-rabbit IgG and Alexa Fluor 488-conjugated goat anti-mouse IgG (Molecular Probes, Eugene, OR, USA).

Statistical methods

Associations between clinicopathological parameters and Reg IV expression were analysed by Fisher's exact test. Kaplan–Meier survival curves were constructed for Reg IV-positive and Reg IV-negative patients. Survival rates were compared between Reg IV-positive and Reg IV-negative groups. The differences between the survival curves between groups were tested for statistical significance by the log-rank test [16]. *p* values less than 0.05 were considered statistically significant.

Results

Expression of REGIV mRNA in neoplastic and non-neoplastic tissues

Quantitative RT-PCR was performed to investigate the specificity of *REGIV* expression. As shown in Figure 1, *REGIV* expression was clearly detected in the stomach, small intestine, colon, and pancreas. High levels of *REGIV* were detected in gastric carcinoma and colorectal carcinoma, whereas *REGIV* expression was not detected in lung or breast cancers.

Figure 1. Quantitative RT-PCR analysis of *REGIV* in various human normal and tumour tissues. Clear *REGIV* expression is present in normal stomach, small intestine, colon, and pancreas. High levels of *REGIV* were observed in some gastric carcinomas and colorectal carcinomas. Expression was not observed in lung or breast cancers. The units are arbitrary and *REGIV* expression was calculated by standardization of 1.0 μg of total RNA from normal stomach as 1.0

Western blotting

The polyclonal anti-Reg IV antibody detected an approximately 17 kD band on western blots of both cell extracts and culture media from MKN-45, MKN-74, HSC-39, and KATO-III cells (Figure 2). These results are consistent with those of previous reports [7,17]. We confirmed that the *REGIV* mRNA levels determined by RT-PCR were consistent with the Reg IV protein levels determined by western blotting. Moreover, we performed western blot analysis of cell extracts of MKN-28 cells transiently transfected with pcDNA 3.1 or pcDNA-Reg IV. We detected an

approximately 17 kD band corresponding to Reg IV. Furthermore, the 17 kD band disappeared with pre-incubation of the antibody with the appropriate Reg IV protein (data not shown).

Immunohistochemical analysis of Reg IV in non-tumour stomach, small intestine, colon, and pancreas

Quantitative RT-PCR revealed obvious *REGIV* expression in non-tumour stomach, small intestine, colon, and pancreas, although the levels were low. We therefore performed immunohistochemical analysis of


Figure 2. Expression of Reg IV in gastric carcinoma cell lines. (A) Western blot analysis of Reg IV with anti-Reg IV antibody. In cell lysates, an approximately 17 kD band is visible in HSC-39 cells after a short exposure. A longer exposure revealed that Reg IV is expressed in MKN-45 and MKN-74 cells. Culture media of MKN-45, MKN-74, and HSC-39 cells contain Reg IV. (B) RT-PCR analysis showed strong expression of *REGIV* in MKN-45, MKN-74, and HSC-39 cells, which is consistent with the western blot results. (C) Western blot analysis of extracts of MKN-28 cells transiently transfected with pcDNA-Reg IV or pcDNA 3.1 (empty vector). With anti-Reg IV antibody, an approximately 17 kD band corresponding to Reg IV is visible. HSC-39 extract served as a positive control

these tissues (Figure 3). In the stomach, foveolar epithelium was negative for Reg IV, whereas goblet cells in intestinal metaplasia showed strong Reg IV expression in goblet cell vesicles (Figure 3A). In addition, neuroendocrine cells at the base of intestinal metaplasia displayed strong Reg IV staining in the perinuclear region (Figures 3A and 3B). All the cells with Reg IV staining of the perinuclear region were positive for chromogranin A; however, chromogranin A-positive cells were not always positive for Reg IV. In general, among neuroendocrine cells of the stomach, as defined by chromogranin A staining, only neuroendocrine cells at the base of intestinal metaplasia were positive for Reg IV. Expression of Reg IV was not detected in stromal cells, such as inflammatory cells and fibroblasts. As described previously [5,7], in the small intestine and colon, only weak or no expression of Reg IV was observed in epithelial cells, whereas strong expression of Reg IV was detected in neuroendocrine cells (Figures 3D, 3E, 3G, and 3H). Although goblet cells of intestinalized stomach, small intestine, and colon were positive for MUC2, only those of intestinal metaplasia of the stomach were positive for Reg IV, and those of the small intestine and colon were negative or weakly positive for Reg IV (Figures 3A, 3C, 3D, 3F, 3G, and 3I). This suggests that goblet cells of intestinal metaplasia of the stomach have different biological characteristics from those of the intestine. Specific immunostaining of gastric, duodenal, or colonic mucosa was not seen with pre-absorbed anti-Reg IV antibody (data not shown). In the pancreas, the insulin-producing beta cells of the endocrine pancreas were positive for Reg IV (Figures 3J–3L).

Immunohistochemical analysis of Reg IV in human tumours

We performed immunohistochemical analysis of Reg IV in 289 human tumour samples. The overall results are summarized in Table 1.

Adenocarcinoma of the stomach

Representative results of Reg IV immunostaining of gastric carcinoma are shown in Figure 4. Of 143 gastric carcinomas, 42 (29.4%) were positive for Reg IV. Reg IV was detected in goblet cell-like vesicles of cancer cells in well-differentiated adenocarcinomas (Figure 4A). Most signet ring cell carcinoma cells were positive for Reg IV (Figure 4C). In some tumour cells, strong Reg IV staining was observed in the perinuclear region (Figures 4B and 4F). We observed two patterns of Reg IV staining, mucin-like staining and strong perinuclear staining, on the basis of AB/PAS staining results. Mucin-like staining was observed in the goblet cells of intestinal metaplasia, goblet cell-like vesicles of well-differentiated adenocarcinoma, signet ring cell carcinomas, and some poorly differentiated adenocarcinomas. In contrast, strong perinuclear staining was detected in neuroendocrine cells at the base of intestinal metaplasia. In well-differentiated adenocarcinoma, neuroendocrine-like cells were positive for Reg IV. In poorly differentiated adenocarcinoma, small tumour cells with scant cytoplasm were positive for Reg IV. Mucin-like staining was observed in 41 of 143 cases and perinuclear staining was found in 17 of 143 cases. There were several gastric carcinomas in which both staining patterns were observed (Table 2). We also analysed the relationship of Reg IV expression to clinicopathological characteristics. Mucin-like

Table 1. Summary of Reg IV protein expression in human tumours

| Organ and histological type	No of cases	No of Reg IV-positive cases		
		Mucin-like	Perinuclear	Total
Stomach				
Adenocarcinoma	143	41 (28.7%)	17 (11.9%)	42 (29.4%)
Colorectum				
Adenocarcinoma	36	13 (36.1%)	0 (0.0%)	13 (36.1%)
Adenoma	10	3 (30.0%)	0 (0.0%)	3 (30.0%)
Carcinoid tumour	15	0 (0.0%)	14 (93.3%)	14 (93.3%)
Pancreas				
Ductal adenocarcinoma	23	5 (21.7%)	0 (0.0%)	5 (21.7%)
Lung				
Squamous cell carcinoma	10	0 (0.0%)	0 (0.0%)	0 (0.0%)
Adenocarcinoma	10	0 (0.0%)	0 (0.0%)	0 (0.0%)
Large cell neuroendocrine carcinoma	10	0 (0.0%)	0 (0.0%)	0 (0.0%)
Breast				
Invasive ductal carcinoma	30	0 (0.0%)	0 (0.0%)	0 (0.0%)
Uterine cervix				
Small cell carcinoma	1	0 (0.0%)	0 (0.0%)	0 (0.0%)
Extrahepatic bile duct				
Small cell carcinoma	1	0 (0.0%)	0 (0.0%)	0 (0.0%)

Figure 3. Immunohistochemical analysis of Reg IV in non-neoplastic human tissues. In the stomach, foveolar epithelium does not express Reg IV (A, red arrowheads). Goblet cell vesicles in goblet cells of intestinal metaplasia are positive for both Reg IV (A) and MUC2 (C). The perinuclear region of neuroendocrine cells at the base of intestinal metaplasia (A and B, black arrows) is positive for Reg IV, whereas in other neuroendocrine cells, as determined by chromogranin A expression (B, black arrowheads), Reg IV is not expressed (A, black arrowheads). In the small intestine and colon, weak or no expression of Reg IV is observed in epithelial cells, whereas strong Reg IV expression is detected in neuroendocrine cells (D, G), as defined by chromogranin A expression (E, H). We confirmed that MUC2 is positive in goblet cells in these samples (F, I). In the pancreas, Reg IV is expressed in beta cells of the endocrine pancreas (J) that express insulin (K). Glucagon-positive alpha cells do not express Reg IV (L). Original magnification: (A–F) ×100; (G–I) ×200; (J–L) ×400. CgA = chromogranin A

Figure 4. Expression and distribution of Reg IV in adenocarcinoma of the stomach. (A) Well-differentiated adenocarcinoma. Reg IV is expressed in goblet cell-like vesicles (black arrowheads). (B) Well-differentiated adenocarcinoma. Strong perinuclear Reg IV staining is present in neuroendocrine-like cells (red arrowheads). We confirmed that these cells are also positive for chromogranin A. (C) Signet ring cell carcinoma. The cytoplasm of tumour cells is positive for Reg IV. (D) Poorly differentiated adenocarcinoma. The cytoplasm of tumour cells is positive for Reg IV. (E) Mucinous adenocarcinoma. The cytoplasm of tumour cells is positive for Reg IV. These three tumour cell types (C, D, and E) show round morphology and are positive for MUC2. (F) Poorly differentiated adenocarcinoma. Strong perinuclear expression of Reg IV is present in tumour cells. These tumour cells are small with scant cytoplasm. Chromogranin A was detected in these cells. Original magnification: ×400

staining of Reg IV was detected more frequently in poorly differentiated adenocarcinoma (41.4%) than in well-differentiated adenocarcinoma (20.0%, $p =$ 0.0081, Fisher's exact test, Table 3). In contrast, no correlation was found between perinuclear Reg IV staining and histological type (Table 3). There was no clear correlation between Reg IV expression and clinical characteristics (Table 3). No statistically significant prognostic impact was found in the group of 52 advanced gastric carcinoma patients or in the group of 24 stage III/IV gastric carcinoma patients (data not shown).

Table 2. Heterogeneity of intracellular localization of Reg IV protein in individual gastric carcinomas

		Mucin-like staining		
		Positive	**Negative**	**p value**
Perinuclear	Positive	16 (94.1%)	1	0.0001
Staining	Negative	25 (19.8%)	101	

We next investigated the association between Reg IV expression and mucin phenotype, because Reg IV was detected in goblet cells of intestinal metaplasia of the stomach. Gastric and intestinal markers were detected in 57 of 143 (39.9%) cases for MUC5AC, 12 (8.4%) cases for MUC6, 52 (36.4%) cases for MUC2, and 17 (11.9%) cases for CD10. Both MUC2 and Reg IV were positive in goblet cell-like vesicles in tumour cells (Figures 5A and 5B), whereas tumour cells with a MUC2-positive perinuclear region were negative for Reg IV (Figures 5C and 5D). We confirmed that tumour cells showing mucin-like staining of Reg IV were positive for MUC2 by double immunofluorescence staining (Figures 5E–5G). Tumour cells with a Reg IV-positive perinuclear region were negative for MUC2 (Figures 5H and 5J). In total, both mucin-like staining and perinuclear Reg IV staining were observed more frequently in MUC2-positive cases (76.9% and 28.8%, respectively) than in MUC2-negative cases (1.1% and 2.2%, $p =$ 0.0001 and $p = 0.0001$, respectively, Fisher's exact test, Table 4). There was no clear relationship between expression of Reg IV and other markers (Table 4). On the basis of the expression of these four markers, we classified the 143 gastric carcinomas phenotypically as 32 (22.4%) G-type, 37 (25.9%) I-type, 28 (19.6%) GI-type, and 46 (32.2%) N-type carcinomas. As expected, mucin-like Reg IV staining was observed only in I-(20/37, 54.1%) and GI-type (21/28, 75.0%) gastric carcinomas. Perinuclear Reg IV staining was observed

in I- (11/37, 29.7%) and GI-type (6/28, 21.4%) gastric carcinomas. Because it has been reported that Cdx2 interacts with the *MUC2* promoter and activates *MUC2* transcription [18], the relationship between Cdx2 and Reg IV was examined. Of 143 gastric carcinomas, 53 (37.1%) were positive for Cdx2. Cdx2 nuclear staining was detected in I- and GI-type carcinomas, but not in G- and N-type carcinomas. Both mucin-like staining and perinuclear staining of Reg IV were observed more frequently in Cdx2-positive cases (35/53, 66.0% and 16/53, 30.2%, respectively) than in Cdx2-negative cases (6/90, 6.7% and 1/90, 1.1%, $p =$ 0.0001 and $p = 0.0001$, respectively, Fisher's exact test, Table 4).

We next examined the relationship between Reg IV and chromogranin A expression in gastric carcinomas. Twenty-seven cases (18.9%) showed chromogranin A staining. Tumour cells with a Reg IV-positive perinuclear region always showed chromogranin A staining, whereas chromogranin A-positive tumour cells were not always positive for Reg IV (Figures 5H and 5I). In total, the frequency of Reg IV-positive (both mucin-like and perinuclear staining) cases was significantly higher among chromogranin A-positive cases (63.0% and 44.4%, respectively) than among chromogranin A-negative cases (20.7% and 4.3%, $p =$ 0.0001 and $p = 0.0001$, respectively, Fisher's exact test, Table 4).

Adenocarcinoma and adenoma of the colorectum

In adenocarcinoma of the colorectum, Reg IV was seen in goblet cell-like vesicles of tumour cells (Figure 6A). In mucinous adenocarcinoma cells and poorly differentiated adenocarcinoma cells, the cytoplasm was also positive for Reg IV (Figures 6B and 6C). In total, 13 (36.1%) of 36 adenocarcinomas of the colorectum were positive for Reg IV, and AB/PAS staining revealed that all of these cases

Table 3. Relationship between Reg IV protein expression and clinicopathological characteristics in gastric carcinoma

|	Reg IV staining								
	Mucin-like			**Perinuclear**			**Total**		
	+	**−**	**p value**	**+**	**−**	**p value**	**+**	**−**	**p value**
T status									
T1	20 (33.9%)	39	NS	6 (10.2%)	53	NS	20 (33.9%)	39	NS
T2/3/4	21 (26.2%)	63		11 (13.1%)	73		22 (26.2%)	62	
N status									
N0	28 (35.0%)	52	NS	11 (13.8%)	69	NS	28 (35.0%)	52	NS
N1/2/3	13 (20.6%)	50		6 (9.5%)	57		14 (22.2%)	49	
Stage									
I/II	33 (32.7%)	68	NS	14 (15.9%)	74	NS	33 (32.7%)	68	NS
III/IV	8 (19.0%)	34		3 (5.5%)	52		9 (21.4%)	33	
Histological type									
Well differentiated	17 (20.0%)	68	0.0081	10 (11.8%)	75	NS	17 (20.0%)	68	0.0047
Poorly differentiated	24 (41.4%)	34		7 (12.1%)	51		25 (43.1%)	33	

NS = not significant.

Figure 5. Co-localization of Reg IV, MUC2, and chromogranin A in gastric carcinoma. Goblet cell-like vesicles of cancer cells are positive for both Reg IV (A) and MUC2 (B). Cancer cells with a MUC2-positive perinuclear region (D) do not express Reg IV (C), although both molecules are present in goblet cell vesicles in intestinal metaplasia (black arrowheads). Double immunofluorescence staining shows that Reg IV (E) is co-expressed with MUC2 (F), but some tumour cells express only MUC2 (G). Perinuclear Reg IV staining co-localizes with chromogranin A staining (H, I, red arrowheads), but not with MUC2 (J). Original magnification: (A–D, H–J) ×400; (E–G) ×200. CgA = chromogranin A

showed mucin-like staining. In contrast to gastric carcinoma, expression of Reg IV by colorectal carcinoma was associated with lymph node metastasis ($p = 0.0379$, Fisher's exact test, Table 5). Moreover, Reg IV staining was observed more frequently in stage III/IV cases (9/16, 56.3%) than in stage I/II cases

Table 4. Relationship between Reg IV protein expression and gastric, intestinal, and neuroendocrine markers in gastric carcinoma

| | Reg IV staining | | | | | | | | |
| | Mucin-like | | | Perinuclear | | | Total | | |
	+	−	p value	+	−	p value	+	−	p value
MUC5AC									
Positive	20 (35.1%)	37	NS	5 (8.8%)	52	NS	20 (35.1%)	37	NS
Negative	21 (24.4%)	65		12 (14.0%)	74		22 (25.6%)	64	
MUC6									
Positive	5 (41.7%)	7	NS	3 (25.0%)	9	NS	5 (41.7%)	7	NS
Negative	36 (27.5%)	95		14 (10.7%)	117		37 (28.2%)	94	
MUC2									
Positive	40 (76.9%)	12	0.0001	15 (28.8%)	37	0.0001	40 (76.9%)	12	0.0001
Negative	1 (1.1%)	90		2 (2.2%)	89		2 (2.2%)	89	
CD10									
Positive	5 (29.4%)	12	NS	4 (23.5%)	13	NS	6 (35.3%)	11	NS
Negative	36 (28.6%)	90		13 (10.3%)	113		36 (28.6%)	90	
Cdx2									
Positive	35 (66.0%)	18	0.0001	16 (30.2%)	37	0.0001	36 (67.9%)	17	0.0001
Negative	6 (6.7%)	84		1 (1.1%)	89		6 (6.7%)	84	
Chromogranin A									
Positive	17 (63.0%)	10	0.0001	12 (44.4%)	15	0.0001	18 (66.7%)	9	0.0001
Negative	24 (20.7%)	92		5 (4.3%)	111		24 (20.7%)	92	

NS = not significant.

(4/20, 20.0%, $p = 0.0379$, Fisher's exact test). Reg IV was detected in three (30.0%) of ten colorectal adenomas. Goblet cell-like vesicles of adenoma cells were stained with Reg IV (Figure 6D).

Ductal adenocarcinoma of the pancreas

In ductal adenocarcinoma of the pancreas, Reg IV was detected in goblet cell-like vesicles or the cytoplasm of cancer cells (Figures 6E and 6F). In total, 5 (21.7%) of 23 ductal adenocarcinomas of the pancreas were positive for Reg IV. These cells were stained

Table 5. Relationship between Reg IV protein expression and clinicopathological characteristics in colorectal carcinoma

| | Reg IV expression | | |
	Positive	Negative	p value
T status			
T1/2	2 (22.2%)	7	0.4379
T3/4	11 (40.7%)	16	
N status			
N0	4 (20.0%)	16	0.0379
N1/2	9 (56.3%)	7	
Stage			
Stage I/II	4 (20.0%)	16	0.0379
Stage III/IV	9 (56.3%)	7	
Histology			
Well/moderately differentiated	8 (26.7%)	22	0.0015*
Poorly differentiated	2 (66.7%)	1	
Mucinous	3 (100.0%)	0	

* Well/moderately vs poorly and mucinous.

with AB/PAS and all of these cases showed mucin-like staining. There was no clear correlation between Reg IV expression and clinicopathological characteristics such as T grade, N grade, and histological differentiation.

Carcinoid tumour (well-differentiated endocrine neoplasm) of the colorectum

Of 15 colorectal carcinoid tumours, 14 (93.3%) were positive for Reg IV. Among these, diffuse strong staining of Reg IV was seen in two (Figure 7A). In the remaining 12, expression of Reg IV was observed focally (data not shown). Co-expression of Reg IV and chromogranin A was observed in some carcinoid tumour cells by double immunofluorescence staining (Figures 7C–7E).

Lung and breast cancer

Ten squamous cell carcinomas and ten adenocarcinomas of the lung were negative for Reg IV. Ten large cell neuroendocrine carcinomas were also negative for Reg IV despite positive chromogranin A staining (Figures 7F and 7G). All 30 invasive ductal carcinomas of the breast were negative for Reg IV (data not shown).

Small cell carcinoma (poorly differentiated endocrine neoplasm) of the uterine cervix and the extrahepatic bile duct

Two small cell carcinomas (uterine cervix and extrahepatic bile duct) were studied. Both were Reg IV-negative but chromogranin A-positive (Figure 7H).

Figure 6. Expression and distribution of Reg IV in adenocarcinoma and adenoma of the colorectum (A–D), and ductal adenocarcinoma of the pancreas (E, F). (A) Well-differentiated adenocarcinoma of the colorectum. Goblet cell-like vesicles of tumour cells express Reg IV. (B) Mucinous adenocarcinoma of the colorectum. The cytoplasm of tumour cells is positive for Reg IV. (C) Poorly differentiated adenocarcinoma of the colorectum. Reg IV is expressed in the cytoplasm. (D) Adenoma of the colorectum. Reg IV is observed in goblet vesicle-like structures in tumour cells. (E, F) Ductal adenocarcinoma of the pancreas. Reg IV is observed in goblet vesicle-like structures or the cytoplasm of tumour cells. Original magnification: (B) ×200; (A, E, F) ×400; (B inset, C, D) ×1000

Discussion

In the present study, we performed immunohistochemical analysis of Reg IV in human tissues. We found that expression of Reg IV is associated with the intestinal mucin phenotype and neuroendocrine differentiation in the stomach and in gastric carcinomas. It is known that Cdx2, a mammalian caudal-related intestinal transcription factor, is important for the maintenance of intestinal epithelial cells

Figure 7. Immunohistochemical analysis of Reg IV in neuroendocrine neoplasms. Diffuse Reg IV staining is visible in carcinoid tumour of the colorectum (A, B). Double immunofluorescence staining shows that Reg IV (C) is co-expressed with chromogranin A (D), but some tumour cells express only chromogranin A. In large cell neuroendocrine carcinoma of the lung (F, G) and small cell carcinoma of the extrahepatic bile duct (H), expression of Reg IV is not detected (F, H). Chromogranin A is positive in all of these tumours (B, G). Original magnification: (C–E) ×200; (A, B, F–H) ×400. CgA = chromogranin A

[19,20]. In addition, several lines of evidence have suggested that intestinal metaplasia of the stomach and gastric adenocarcinoma with the intestinal mucin phenotype are associated with ectopic Cdx2 expression [21–24]. Because it has been reported that Cdx2 interacts with the *MUC2* promoter and activates *MUC2* transcription [18], Cdx2 may regulate transcription of the *REGIV* gene. In the present study, expression of Reg IV correlated with Cdx2 expression in gastric

carcinomas, suggesting that Cdx2 is associated with Reg IV expression. However, ectopic expression of Cdx2 alone cannot explain the expression of Reg IV in intestinal metaplasia of the stomach and in gastric carcinoma with the intestinal mucin phenotype, because expression of Reg IV was weak or absent in the small intestine and colon, both of which express Cdx2. Furthermore, gastric carcinoma cells with a MUC2-positive perinuclear region were negative for Reg IV.

These results suggest that goblet cells of intestinal metaplasia of the stomach may have different biological characteristics from those of the small intestine and colon. In fact, the proliferative activity of goblet cells in intestinal metaplasia of the stomach is higher than that of goblet cells in normal small intestine [25]. Up-regulation of Reg IV in goblet cells of the colon has been reported in inflammatory bowel disease [4,7]. Cdx2 and other factors are needed to express Reg IV. Therefore, in intestinal metaplasia of the stomach and gastric carcinoma with the intestinal mucin phenotype, mechanisms in addition to expression of Cdx2 may be involved. Additional investigation will clarify whether Cdx2 induces Reg IV expression.

In the present study, only neuroendocrine cells at the base of intestinal metaplasia in non-neoplastic stomach were positive for Reg IV. A possible link between intestinal metaplasia of the stomach and neuroendocrine cells has been observed in *neurogenin 3* knockout mice [26]. In these mice, intestinal metaplasia occurs in the stomach, and glucagon-secreting A-cells, somatostatin-secreting D-cells, and gastrin-secreting G-cells are absent, whereas the number of serotonin-expressing enterochromaffin cells is decreased but present. These data suggest that the neuroendocrine cells at the base of intestinal metaplasia may have origins different from those of other neuroendocrine cells. Reg IV-positive neuroendocrine cells may be positive for serotonin.

We observed two Reg IV staining patterns, namely mucin-like staining and strong perinuclear staining. Mucin-like staining was observed in goblet cells, signet ring cell carcinomas, some poorly differentiated gastric adenocarcinomas, and some adenocarcinomas of the colorectum and pancreas. These cells were positive for MUC2 and AB/PAS. In contrast, strong perinuclear staining was detected in neuroendocrine cells at the base of intestinal metaplasia of the stomach, small intestine, and colon. In well-differentiated adenocarcinoma of the stomach, neuroendocrine-like cells were positive for Reg IV. In poorly differentiated adenocarcinoma of the stomach, small tumour cells with scant cytoplasm were positive for Reg IV. Carcinoid tumour cells were also positive for Reg IV. Chromogranin A, but not MUC2, was expressed by these cells. The significance of the difference between the Reg IV staining patterns is not clear. However, there were several gastric carcinomas in which both staining patterns were observed and we presume that these staining patterns are not independent.

There was substantial variability in the *REGIV* mRNA levels between different samples taken from gastric carcinomas and colorectal carcinomas. *REGIV* is expressed in both normal stomach and colon tissues, but expression was not detected in four samples of gastric carcinoma and was very low in two colorectal carcinoma samples. Because bulk tissues were used for quantitative RT-PCR analysis, the resulting data may not reflect the expression levels of Reg IV in tumour cells alone. Reg IV-positive cells were

observed in intestinal metaplastic glands, suggesting that a sample of normal stomach used for quantitative RT-PCR may contain foci of intestinal metaplasia. In the present study, several cancer samples showed no Reg IV staining, whereas several cancer samples showed extensive Reg IV staining, resulting in the large variability in *REGIV* mRNA levels determined by quantitative RT-PCR.

The biological function of Reg IV is poorly understood. Because it is associated with 5-FU resistance, Reg IV may be involved in apoptosis resistance. I- and GI-type gastric carcinomas are reported to show high 5-FU resistance [27]. Reg IV is also thought to be a candidate marker of stem cells in the intestine [17]. Although Regenerating gene I (Reg I) is expressed in foveolar neck cells [28], some of which are thought to be stem cells of the stomach, we did not observe expression of Reg IV in foveolar neck cells in the present study. Thus, Reg IV is not a marker of stem cells, at least in the stomach. In colorectal adenomas and carcinomas, mucin-like staining of Reg IV protein was observed. The adenoma–carcinoma sequence describes the development of sporadic colorectal carcinoma from pre-cancerous adenomatous mucosal lesions [29]. Dysregulation of Reg IV expression may be associated with an early step in the adenoma–carcinoma sequence.

Is the detection of Reg IV expression of clinical benefit? Previously, we identified *REGIV* as a cancer-specific (at least gastric cancer-specific) gene by SAGE and quantitative RT-PCR analysis of bulk gastric carcinoma tissues [3]. In the present study, we did not detect expression of Reg IV in normal foveolar epithelium of the stomach; however, Reg IV-positive cells were observed in non-neoplastic tissues. Thus, Reg IV does not appear to be a true cancer-specific marker. However, expression of Reg IV was associated with both lymph node metastasis and tumour stage in colorectal carcinoma. Moreover, carcinoid tumours of the colorectum were positive for Reg IV, whereas large cell neuroendocrine carcinomas of the lung and small cell carcinomas of the uterine cervix and the extrahepatic bile duct were all negative for Reg IV. Reg IV was not expressed by squamous cell carcinomas and adenocarcinomas of the lung, or by invasive ductal carcinomas of the breast. Therefore, Reg IV may be a good marker for gastrointestinal and pancreatic tumours.

In conclusion, our present study provides detailed information about the expression and distribution of Reg IV in various neoplastic and non-neoplastic human tissues. Reg IV expression is associated with gastrointestinal and pancreatic carcinoma and carcinoid tumours. Because there are many types of tumour, further investigation is needed to establish the specificity of Reg IV for gastrointestinal and pancreatic tumours. The difference between Reg IV expression in goblet cells of intestinal metaplasia of the stomach and those of the intestine may possibly explain

the differences between metaplastic and normal cells, even though the histological appearance is similar.

Acknowledgements

References

1. Buckhaults P, Rago C, St Croix B, Romans KE, Saha S, Zhang L, et al. Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res 2001;61:6996–7001.

2. Yasui W, Oue N, Ito R, Kuraoka K, Nakayama H. Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci 2004;95:385–392.

3. Oue N, Hamai Y, Mitani Y, Matsumura S, Oshimo Y, Aung PP, et al. Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res 2004;64:2397–2405.

4. Hartupee JC, Zhang H, Bonaldo MF, Soares MB, Dieckgraefe BK. Isolation and characterization of a cDNA encoding a novel member of the human regenerating protein family: Reg IV. Biochim Biophys Acta 2001;1518:287–293.

5. Violette S, Festor E, Pandrea-Vasile I, Mitchell V, Adida C, Dussaulx E, et al. Reg IV, a new member of the regenerating gene family, is overexpressed in colorectal carcinomas. Int J Cancer 2003;103:185–193.

6. Zhang Y, Lai M, Lv B, Gu X, Wang H, Zhu Y, et al. Overexpression of Reg IV in colorectal adenoma. Cancer Lett 2003;200:69–76.

7. Kamarainen M, Heiskala K, Knuutila S, Heiskala M, Winqvist O, Andersson LC. RELP, a novel human REG-like protein with up-regulated expression in inflammatory and metaplastic gastrointestinal mucosa. Am J Pathol 2003;163:11–20.

8. Kuraoka K, Taniyama K, Fujitaka T, Nakatsuka H, Nakayama H, Yasui W. Small cell carcinoma of the extrahepatic bile duct: case report and immunohistochemical analysis. Pathol Int 2003;53:887–891.

9. Sobin LH, Wittekind CH (eds). TNM Classification of Malignant Tumors (5th edn). Wiley-Liss: New York, 1997; 59–62.

10. Ochiai A, Yasui W, Tahara E. Growth-promoting effect of gastrin on human gastric carcinoma cell line TMK-1. Jpn J Cancer Res 1985;76:1064–1071.

11. Yanagihara K, Seyama T, Tsumuraya M, Kamada N, Yokoro K. Establishment and characterization of human signet ring cell gastric carcinoma cell lines with amplification of the c-myc oncogene. Cancer Res 1991;51:381–386.

12. Kondo T, Oue N, Yoshida K, Mitani Y, Naka K, Nakayama H, et al. Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma. Cancer Res 2004;64:523–529.

13. Yasui W, Ayhan A, Kitadai Y, Nishimura K, Yokozaki H, Ito H, et al. Increased expression of p34cdc2 and its kinase activity in human gastric and colonic carcinomas. Int J Cancer 1993;53:36–41.

14. Yasui W, Ji ZQ, Kuniyasu H, Ayhan A, Yokozaki H, Ito H, et al. Expression of transforming growth factor alpha in human tissues: immunohistochemical study and northern blot analysis. Virchows Arch A Pathol Anat Histopathol 1992;421:513–519.

15. Mizoshita T, Tsukamoto T, Nakanishi H, Inada K, Ogasawara N, Joh T, et al. Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis. J Cancer Res Clin Oncol 2003;129:727–734.

16. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163–170.

17. Li A, Crimmins DL, Luo Q, Hartupee J, Landt Y, Ladenson JH, et al. Expression of a novel regenerating gene product, Reg IV, by high density fermentation in Pichia pastoris: production, purification, and characterization. Protein Expr Purif 2003;31:197–206.

18. Yamamoto H, Bai YQ, Yuasa Y. Homeodomain protein CDX2 regulates goblet-specific MUC2 gene expression. Biochem Biophys Res Commun 2003;300:813–818.

19. Mallo GV, Rechreche H, Frigerio JM, Rocha D, Zweibaum A, Lacasa M, et al. Molecular cloning, sequencing and expression of the mRNA encoding human Cdx1 and Cdx2 homeobox. Down-regulation of Cdx1 and Cdx2 mRNA expression during colorectal carcinogenesis. Int J Cancer 1997;74:35–44.

20. Silberg DG, Swain GP, Suh ER, Traber PG. Cdx1 and cdx2 expression during intestinal development. Gastroenterology 2000;119:961–971.

21. Silberg DG, Sullivan J, Kang E, Swain GP, Moffett J, Sund NJ, et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 2002;122:689–696.

22. Bai YQ, Yamamoto H, Akiyama Y, Tanaka H, Takizawa T, Koike M, et al. Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. Cancer Lett 2002;176:47–55.

23. Almeida R, Silva E, Santos-Silva F, Silberg DG, Wang J, De Bolos C, et al. Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J Pathol 2003;199:36–40.

24. Tatematsu M, Tsukamoto T, Inada K. Stem cells and gastric cancer: role of gastric and intestinal mixed intestinal metaplasia. Cancer Sci 2003;94:135–141.

25. Wong WM, Stamp GW, Elia G, Poulsom R, Wright NA. Proliferative populations in intestinal metaplasia: evidence of deregulation in Paneth and goblet cells, but not endocrine cells. J Pathol 2000;190:107–113.

26. Lee CS, Perreault N, Brestelli JE, Kaestner KH. Neurogenin 3 is essential for the proper specification of gastric enteroendocrine cells and the maintenance of gastric epithelial cell identity. Genes Dev 2002;16:1488–1497.

27. Tajima Y, Shimoda T, Nakanishi Y, Yokoyama N, Tanaka T, Shimizu K, et al. Association of gastric and intestinal phenotypic marker expression of gastric carcinomas with tumor thymidylate synthase expression and response to postoperative chemotherapy with 5-fluorouracil. J Cancer Res Clin Oncol 2003;129:683–690.

28. Dhar DK, Udagawa J, Ishihara S, Otani H, Kinoshita Y, Takasawa S, et al. Expression of regenerating gene I in gastric adenocarcinomas: correlation with tumor differentiation status and patient survival. Cancer 2004;100:1130–1136.

29. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138–141.

DNA Methylation of Genes Linked with Retinoid Signaling in Gastric Carcinoma

Expression of the Retinoid Acid Receptor β, Cellular Retinol-Binding Protein 1, and Tazarotene-Induced Gene 1 Genes Is Associated with DNA Methylation

Mariko Shutoh, M.D.[1,2]
Naohide Oue, M.D., Ph.D.[1]
Phyu Phyu Aung, M.B.B.S.[1]
Tsuyoshi Noguchi, M.D., Ph.D.[2]
Kazuya Kuraoka, M.D., Ph.D.[1]
Hirofumi Nakayama, M.D., Ph.D.[1]
Katsunobu Kawahara, M.D., Ph.D.[2]
Wataru Yasui, M.D., Ph.D.[1]

[1] Department of Molecular Pathology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan.

[2] Department of Oncological Science (Surgery II), Faculty of Medicine, Oita University, Oita, Japan.

BACKGROUND. Hypermethylation of CpG islands has been associated with silencing of various tumor suppressor genes, and the retinoid acid receptor β (RARβ), cellular retinol-binding protein 1 (CRBP1), and tazarotene-induced gene 1 (TIG1) genes have been associated with retinoic acid signaling. To the authors' knowledge, little is known regarding the involvement of these three genes in gastric carcinoma (GC). In this study, the authors investigated the methylation status of these genes and analyzed the role of their DNA methylation in GC.

METHODS. DNA methylation of 3 retinoic acid-associated genes was analyzed in 42 samples of GC from 42 patients and in 8 GC cell lines by methylation-specific polymerase chain reaction (PCR) analysis. The mRNA expression levels for these three genes were measured by quantitative reverse transcription-PCR.

RESULTS. In 7 of 8 GC cell lines, the CRBP1 gene was hypermethylated, and CRBP1 transcription was inactive. In 6 of 8 GC cell lines, the TIG1 gene was hypermethylated, and TIG1 transcription was inactive. Treatment with demethylating agent 5-aza-2'-deoxycytidine restored both CRBP1 and TIG1 transcription. DNA methylation of the RARβ, CRBP1, and TIG1 genes was detected in 15 of 42 GC samples (36%), 14 of 42 GC samples (33%), and 4 of 42 GC samples (10%), respectively, and in 6 of 30 samples (20%), 0 of 30 samples (0%), and 1 of 30 samples (3%) of corresponding nonneoplastic mucosa. None of the 10 normal gastric mucosa samples from young, healthy individuals demonstrated hypermethylation of any of these genes. DNA methylation of each gene was associated significantly with low mRNA expression of the respective gene. Twenty-four of 42 GC samples (57%) demonstrated hypermethylation of at least 1 of the 3 genes. However, no significant, concordant hypermethylation of these genes was observed.

CONCLUSIONS. The results suggested that gastric carcinogenesis involves transcriptional inactivation by aberrant DNA methylation of genes related to retinoid signaling. Cancer 2005;104:1609–19. © 2005 American Cancer Society.

KEYWORDS: DNA methylation, gastric carcinoma, retinoic acid, cellular retinol-binding protein 1, tazarotene-induced gene 1.

Various genetic and epigenetic alterations are associated with gastric carcinoma (GC).[1,2] Epigenetic alterations, such as DNA methylation of CpG islands, are common in human malignancies. Hypermethylation of CpG islands is associated with the silencing of several genes and has been proposed as a mechanism for inactivation of tumor suppressor genes in carcinoma.[3,4] The identification of methylated genes may be useful in the diagnosis and treatment of carcinoma and may provide insight into gastric carcinogenesis. It has been demonstrated that DNA hypermethylation is a crucial mechanism for

transcriptional silencing of tumor suppressor genes and tumor-related genes in GC[5–8] and that DNA methylation of tumor suppressor genes occurs in early-stage GC and accumulates along the multiple pathways of gastric carcinogenesis.[9]

A frequently hypermethylated gene, not only in GC but also in breast and lung carcinomas, is retinoic acid receptor β (*RARβ*).[10–12] Retinoids regulate the growth, differentiation, and apoptosis of normal cells during embryonic development and of premalignant and malignant cells during carcinogenesis. The effects of retinoids are mediated predominantly by the RARs (RARα, RARβ, and RARγ), which act as retinoic acid-dependent transcriptional activators in heterodimeric association with the retinoid X receptors (RXRα, RXRβ, and RXRγ) and in conjunction with multiple corepressors.[13,14] RARs can induce the expression of certain genes in a ligand-dependent manner by binding to retinoic acid-responsive elements in the promoter regions.

Other key components of retinoid signaling include cellular retinol-binding proteins (CRBPs), which belong to the family of fatty acid-binding proteins. Three CRBP members have been described: *CRBP1*, which is expressed widely,[15] and *CRBP2* and *CRBP3*, which demonstrate tissue-specific expression.[16,17] Retinoic acid is present in the circulation, and most tissues rely on the uptake and cytosolic metabolism of retinoic acid to activate RARs and RXRs. CRBPs possess high-affinity binding for retinoic acid and possibly function as chaperone-like proteins to regulate the prenuclear phase of retinoic acid signaling.[16] A critical role of CRBP1 was demonstrated in *CRBP1* knock-out mice, which are susceptible to hypovitaminosis A syndrome.[18] The *CRBP1* gene is hypermethylated in various human malignancies.[19] Possible involvement of *CRBP2* in N-methyl-N'-nitro-N-nitrosoguanidine-induced rat stomach carcinogenesis has been reported.[20] However, to our knowledge, little is known regarding the DNA methylation status of *CRBP1* in GC.

Tazarotene, which is a synthetic retinoid that binds RARβ and RARγ, is used in the treatment of psoriasis, a hyperproliferative disorder. One gene induced by tazarotene is tazarotene-induced gene 1 (*TIG1*).[21] The *TIG1* gene also is hypermethylated in various human malignancies.[22,23] TIG1 may function as a cell adhesion molecule, and its expression on the cell surface may increase cell-cell contact and reduce proliferation.[24] Therefore, it is important to consider the potential function of TIG1 and its role in RAR-mediated biology. *TIG1* has been identified as a potential tumor suppressor gene in human prostate carcinoma.[24] However, to our knowledge, DNA

hypermethylation of the *TIG1* gene in GC has not been investigated.

In the current study, we examined the methylation status of the *RARβ*, *CRBP1*, and *TIG1* genes and the expression levels of these genes in 42 primary GC samples and in corresponding samples of nonneoplastic mucosa. To determine whether hypermethylation induced transcriptional inactivation, we compared methylation status with mRNA expression. We also examined whether correlations exist between the methylation status of each of these genes.

MATERIALS AND METHODS
Cell Lines
Eight cell lines derived from human GC were used. The TMK-1 cell line was established in our laboratory from a poorly differentiated adenocarcinoma.[25] Five GC cell lines of the MKN series (MKN-1, adenosquamous cell carcinoma; MKN-7; MKN-28; MKN-74, well differentiated adenocarcinoma; and MKN-45, poorly differentiated adenocarcinoma) kindly were provided by Dr. T. Suzuki. The KATO-III and HSC-39 cell lines, which were established from signet ring cell carcinomas, kindly were provided by Dr. M. Sekiguchi and Dr. K. Yanagihara, respectively.[26] All cell lines were maintained in RPMI 1640 (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) containing 10% fetal bovine serum (Whittaker, Walkersville, MD) in a humidified atmosphere of 5% CO_2 and 95% air at 37 °C. To analyze restoration of *CRBP1* and *TIG1* gene expression, MKN-28 cells were incubated for 5 days with 1 μM Aza-2'-deoxycytidine (Aza-dC; Sigma Chemical Company, St. Louis, MO).

Tissue Samples
Frozen tissue samples were collected from 42 patients with GC who underwent surgery between 1998 and 2001 at the Department of Oncological Science, Oita University Hospital (Oita, Japan). All patients underwent curative resection. GC tissue specimens from 42 patients were analyzed for methylation of the *RARβ*, *CRBP1*, and *TIG1* genes. Thirty samples of corresponding nonneoplastic mucosa, including 22 samples with intestinal metaplasia, also were analyzed. Tumors and corresponding nonneoplastic mucosa were removed surgically, immediately frozen in liquid nitrogen, and stored at − 80 °C until use. We confirmed microscopically that the tumor tissue specimens consisted mainly (> 50%, on a nuclear basis) of tumor tissue and that nonneoplastic mucosa did not exhibit any tumor cell invasion or show significant inflammatory involvement. *Helicobacter pylori* status was confirmed by histology and/or ^{13}C-urea breath